Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2026)

Rigel Pharmaceuticals' Total Debt history runs 8 years deep, the most recent figure standing at $44.9 million for Q1 2026.

• On a quarterly basis, Total Debt fell 24.92% year-over-year to $44.9 million in Q1 2026; TTM through Mar 2026 was $44.9 million, a 24.92% decrease from a year earlier, with the FY2025 full-year figure at $82.1 million, up 22.63% from the prior year.
• Total Debt retreated to $44.9 million in Q1 2026 per RIGL's latest filing, from $82.1 million in the prior quarter.
• Across five years, Total Debt topped out at $82.1 million in Q4 2025 and bottomed at $29.8 million in Q2 2022.
• The 5-year median for Total Debt is $59.7 million (2023), against an average of $54.7 million.
• Across the five-year window, Total Debt soared 99.68% in 2023 and dropped 24.92% in 2026, its largest moves.
• Year by year, Total Debt stood at $39.4 million in 2022, then jumped by 51.09% to $59.6 million in 2023, then increased by 12.33% to $67.0 million in 2024, then rose by 22.63% to $82.1 million in 2025, then tumbled by 45.37% to $44.9 million in 2026.
• Per Business Quant, the three latest RIGL Total Debt figures stand at $44.9 million (Q1 2026), $82.1 million (Q4 2025), and $59.7 million (Q3 2025).